Quality of life among ovarian cancer survivors in Haji Adam Malik General Hospital Medan, Indonesia
Abstract
Latar belakang: Kanker ovarium memiliki angka mortalitas yang cukup tinggi dikarenakan gejalanya yang tidak spesifik, sering ditemukan pada stadium lanjut, dan belum adanya metode deteksi dini yang sudah terbukti. Untuk menilai keberhasilan terapi penyintas kanker ovarium, tidak hanya dinilai dari aspek klinis tetapi juga dinilai dari kualitas hidup penyintas kanker ovarium yang penilaiannya berdasarkan skala fungsional dan skala gejala dalam kuesioner EORTC QLQ C30 dan EORTC QLQ OV28.
Metode: Penelitian ini menggunakan desain penelitian cross sectional, menggunakan data primer dari hasil wawancara dengan kuesioner EORTC QLQ C30 dan EORTC QLQ OV28 serta data sekunder yang berasal dari rekam medik di RSUP Haji Adam Malik Medan tahun 2017 - 2018. Sampel penelitian dipilih dengan metode total sampling dari seluruh data rekam medik yang memenuhi kriteria penelitian.
Hasil: Hasil penelitian ini didapatkan kualitas hidup global penyintas kanker ovarium 89.36% adalah baik, dan 10.64% adalah sedang serta tidak ada yang memiliki kualitas hidup buruk. Namun, didapatkan adanya gangguan pada skala fungsional berupa: fungsi emosional, fungsi kognitif, fungsi seksual, dan sikap terhadap penyakit, serta adanya permasalahan pada skala gejala berupa: kelelahan, nyeri, neuropati perifer, dan gejala menopause. Didapatkan juga tidak ada hubungan karakteristik usia, jenis histopatologis, stadium, lama terapi dengan kualitas hidup penyintas kanker ovarium, namun terdapat hubungan antara jenis terapi dengan kualitas hidup penyintas kanker ovarium.
Kesimpulan: Kualitas hidup penyintas kanker ovarium secara global adalah baik.
Kata Kunci: Kualitas Hidup, Penyintas Kanker Ovarium, EORTC QLQ C-30, EORTC QLQ OV-28
Abstract
Background: Ovarian cancer has a high mortality rate due to nonspecific symptoms, often found at an advanced stage, and also the absence of proven early detection methods. To assess the success of ovarian cancer survivors therapy, it is not only assessed from the clinical aspect but also from the quality of life of ovarian cancer survivors which is based on the functional and symptom scale in the EORTC QLQ C30 and EORTC QLQ OV28 questionnaires.
Methods: This study used a cross-sectional study design, using primary data from interviews with the survivors based on the questionnaire EORTC QLQ C30 and EORTC QLQ OV28 as well as secondary data derived from medical records at Haji Adam Malik General Hospital Medan in 2017 - 2018. The research sample was used with a total sampling method from all medical record data that fulfill the research criteria.
Result: The quality of life of ovarian cancer survivors is generally good (89.36%), meanwhile the rest is moderate (10.64%) without the poor quality of life. However, there are disorders on the functional scale in the form of emotional function, cognitive function, sexual function, and attitude toward disease. Likewise on the scale of symptoms, there are problems including: fatigue, pain, peripheral neuropathy, and menopausal symptoms.
Conclusion: The quality of life of ovarian cancer survivors globally is good.
Keywords: Quality of Life, Ovarian Cancer Survivors, EORTC QLQ C-30, EORTC QLQ OV-28
References
Aziz MF. Gynecological cancer in Indonesia. J Gynecol Oncol. 2009;20(1):8-10.
Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinician. 2018; 68:394–424.
Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61(2): 69-90.
Farghaly SA. Quality of life in patients with ovarian cancer : advances in diagnosis and management of ovarian cancer. Department of Obstetrics and Gynecology Weill Cornell Medical College The New York Presbyterian Hospital-Weill Cornell Medical Center Cornell University New York, NY USA; 2014. p.241–260.
Goncalvez V, Padilla ID. Quality of life in ovarian cancer treatment and survivorship. A Clinical and Translational Update. Consultant Medical Oncologist. Hospital Universitario HM Sanchinarro; 2013. p.27-48.
Riska HP. Kualitas hidup pasien kanker ginekologi yang menjalani terapi. Aisyah: Jurnal Ilmu Kesehatan Indonesia. 2017; 5(2):69-74. Indonesian.
Noviyani R, Tunas IK, Indrayathi A, Budiana NG. Uji validitas dan reliabilitas kuesioner EORTC QLQ C30 untuk menilai kualitas hidup pasien kanker ginekologi di RSUP Sanglah Denpasar. Jurnal Farmasi Klinik Indonesia. 2016; 5(2):106-14. Indonesian.
Leng T, Ching S, Idris D, Wah T, Yue L, Yen C, et al. Validation of EORTC QLQ-C30 and QLQ-BR23 questionnaires in the measurement of quality of life of breast cancer patients in Singapore. Asia-Pasific Journal of Oncology Nursing. 2014; 1(1):22-32.
Dinkelspiel HE, Tergas AI, Zimmerman LA, Burke WM, Hou JY, Chen L, et al. Use and duration of chemotherapy and its impact on survival in early stage ovarian cancer. Gynecol Oncol PMC. 2015;137(2): 203–9.
Bhugwandass CS, Pijnenborg JMA, Pijlman B, Ezendam NPM. Effect of chemotherapy on health-related quality of life among early-stage ovarian cancer survivors: a study from the population-based profiles registry. Current Oncology A Canadian Cancer Research Journal. 2016; 23(6): e556–e562.
American Society Disorder 2018. Cancer Facts and Figures 2018. Atlanta: American Cancer Society; 2018. p. 28 – 39.
Brett MR, Jennifer BP, Thomas AS. Epidemiology of ovarian cancer: a review. Cancer Biol Med. 2017;14(1): 9–32.
Lee JY, Kim S, Kim YT, Lim MC, Lee B, Jung KW, et al.. Change in ovarian cancer survival during the 20 years before the era of targeted therapy. BMC Cancer. 2018;18:601-8.
Fayers PM, Aaronson NK, Bjordal K, Groenvold M, Curran D, Bottomley A. The EORTC QLQ-C30 scoring manual, 3rd ed., Brussels, European Organization for Research and Treatment of Cancer.2001. The European Organisation for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. Journal of the National Cancer Institute. Available from: http://www.eortc.be/home/qol/files/SC/Manual QLQ-C30.pdf
Greimel E, Daghofer F, Petru E. Prospective assesment of quality of life in long term ovarian cancer survivors. International Journal of cancer. 2011;128(12):3005-11.
Roland KB, Rodriguez JL, Patterson JR, Trivers KF. A literature review of the social and psychological needs of ovarian cancer survivors. Psycho-Oncology. 2013;22(11):2408–18.
Correa DD, Zhou Q, Thaler HT, Maziarz M, Hurley K, Hensley ML. Cognitive functions in long-term survivors of ovarian cancer. Gynecologic Oncology. 2010;119(2):366–9.
Sekse RJT, Hufthammer KO, Vika ME. Fatigue and quality of life in women treated for various types of gynaecological cancers: a cross-sectional study. Journal of Clinical Nursing. 2014;24(3-4):546–55.
Glare PA, Davies PS, Finlay E, Gulati A, Lemanne D, Moryl, et al. Pain in cancer survivors. Journal of Clinical Oncology. 2014;32(16):1739–47.
Hopkins TG, Stavraka C, Gabra H, Fallowfield L, Hood C, Blagden S. Sexual activity and functioning in ovarian cancer survivors: an internet-based evaluation. Climacteric, 2014;18(1):94–8.
Staff NP, Grisold A, Grisold W, Windebank AJ. Chemotherapy-induced peripheral neuropathy: a current review. Annals of Neurology. 2017;81(6):772–81.
Teng FF, Kalloger SE, Brotto L, McAlpine JN. Determinants of quality of life in ovarian cancer survivors: a pilot study. Journal of Obstetrics and Gynaecology Canada. 2014;36(8):708–15.
Wright AA, Pereira L, Nilsson L, Gibson C, Campos SM, Roche M, et al. Associations between age and quality of life in advanced ovarian cancer. Journal of Clinical Oncology 28. 2010;5085-5085.
Mirabeau-Beale KL, Kornblith AB, Penson RT, Lee H, Goodman A, Campos, et al. Comparison of the quality of life of early and advanced stage ovarian cancer survivors. Gynecologic Oncology.2009; 114(2).
Ji J, Försti A, Sundquist J, Lenner P, Hemminki K. Survival in ovarian cancer patients by histology and family history. Acta Oncologica. 2008;247(6):1133–9.
Copyright (c) 2020 Kristivani Br Ginting
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
